All kit components of this kit are stable at 2 to 8°C. Any unused reconstituted standard should be discarded or frozen at -70°C. Standard can be frozen and thawed one time only without loss of immunoreactivity.
< 15.45 pg/ml
Sample Type :
Human serum, plasma, cell lysate, culture supernatants, buffered soltuion
Interleukin-3 (IL-3) is an interleukin, a type of biological signal (cytokine) that can improve the body's natural response to disease as part of the immune system. It acts by binding to the interleukin-3 receptor. IL-3 stimulates the differentiation of multipotent hematopoietic stem cells into myeloid progenitor cells or, with the addition of IL-7, into lymphoid progenitor cells. Additionally, IL-3 stimulates proliferation of all cells in the myeloid lineage (granulocytes, monocytes, and dendritic cells), in conjunction with other cytokines, e.g., Erythropoietin (EPO), Granulocyte macrophage colony-stimulating factor (GM-CSF), and IL-6. It is secreted by basophils and activated T cells to support growth and differentiation of T cells from the bone marrow in an immune response. Activated T cells can either induce their own proliferation and differentiation (autocrine signalling), or that of other T cells (paracrine signalling) - both involve IL-2 binding to the IL-2 receptor on T cells (upregulated upon cell activation, under the induction of macrophage-secreted IL-1). The human IL-3 gene encodes a protein 152 amino acids long, and the naturally occurring IL-3 is glycosylated. The human IL-3 gene is located on chromosome 5, only 9 kilobases from the GM-CSF gene, and its function is quite similar to GM-CSF.
Background reference :
1) Smith KA, Lachman LB, Oppenheim JJ, Favata MF (June 1980). "The functional relationship of the interleukins". J. Exp. Med. 151 (6): 1551–6.
2) Smith KA, Gilbride KJ, Favata MF (October 1980). "Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells". Nature 287 (5785): 853–5.
3) Robb RJ, Smith KA (December 1981). "Heterogeneity of human T-cell growth factor(s) due to variable glycosylation". Mol. Immunol. 18 (12): 1087–94.
4) Smith KA, Favata MF, Oroszlan S (October 1983). "Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics". J. Immunol. 131 (4): 1808–15.